Lundbeck第3阶段的MASCOT试验将测试 Amlenetug是否减缓了美国、欧盟和日本的多重系统萎缩进程 Lundbeck's Phase 3 MASCOT trial will test if amlenetug slows Multiple System Atrophy progression in U.S., EU, and Japan.

Lundbeck将在2025年帕金森病和运动紊乱国际大会上介绍Amerentug第3阶段的MASCOT试验设计,这是针对多种系统萎缩中的α子核素(MSA)的调查性抗体。 Lundbeck will present the Phase 3 MASCOT trial design for amlenetug, an investigational antibody targeting α-synuclein in Multiple System Atrophy (MSA), at the 2025 International Congress of Parkinson's Disease and Movement Disorders. 这项在美国,欧盟和日本进行的试验采用适应贝叶斯方法,评估amlenetug是否可以减缓MSA的进展,这是一种罕见的,迅速发展的疾病,没有批准的治疗方法. The trial, ongoing in the U.S., EU, and Japan, uses an adaptive Bayesian approach to evaluate whether amlenetug can slow MSA progression, a rare, rapidly advancing disorder with no approved treatments. Amleentug在美国和欧盟有孤儿药品指认,在日本有SAKIGAKAKEKE地位。 Amlenetug has Orphan Drug Designation in the U.S. and EU, and SAKIGAKE status in Japan. 患者和护理人员从之前的第二阶段试验中获得的见解为设计提供了信息,强调了MSA对日常生活的严重影响. Patient and caregiver insights from a prior Phase 2 trial informed the design, emphasizing MSA’s severe impact on daily life.